← back to search

Lin Wang

Nanjing University of Chinese Medicine · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Apatinib and Gastroesophageal Junction, with related work in Proteinuria, Multicenter study, Cancer. Notable publications include 'Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a...', 'Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201)', and 'Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201)'.
h-index
citations
31
works
5
NIH funding
primary concept
email

Recent publications

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
BMC Medicine 2023cited by 30position: middledoi
Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201).
Journal of Clinical Oncology 2018cited by 1position: middledoi
Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).
Journal of Clinical Oncology 2018cited by 0position: middledoi
Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201).
Journal of Clinical Oncology 2018cited by 0position: middledoi
Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201).
Journal of Clinical Oncology 2018cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Junsheng Wang · Qingdao University4 papers (2018–2018)Jianwei Yang · UCLA Health4 papers (2018–2018)Guifang Zhang · Dalian Medical University4 papers (2018–2018)Xiaoyan Lin · Virginia Tech4 papers (2018–2018) · 4 papers (2018–2018)Yifu He · Ministry of Education4 papers (2018–2018)Likun Liu · Hebei Medical University4 papers (2018–2018)Min Tao · Zhejiang Chinese Medical University4 papers (2018–2018) · 4 papers (2018–2018)Congying Xie · Sun Yat-sen University Cancer Center4 papers (2018–2018)Yi Ba · Henan Cancer Hospital4 papers (2018–2018)Lu Wen · Union Hospital4 papers (2018–2018)Wenying Deng · Regeneron (United States)4 papers (2018–2018)Yuxian Bai · Harbin Medical University4 papers (2018–2018)Xiangyuan Wu · Sun Yat-sen University3 papers (2018–2018)Shukui Qin · Affiliated Hospital of Southwest Medical University3 papers (2018–2018)Mei Wang · Tianjin University3 papers (2018–2018)Jin Li · Xinjiang University3 papers (2018–2018)Feng Ye · Sichuan University3 papers (2018–2018)Feng Ye · State Grid Corporation of China (China)1 papers (2018–2018)